PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Test Name
Test Title, Test Company

Read biography×

PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Newton Crenshaw
Vice President, Lilly Oncology Global Business Development and Advocacy, Eli Lilly and Company

Read biography×

Newton Crenshaw
Vice President, Lilly Oncology Global Business Development and Advocacy, Eli Lilly and Company

Follow Newton on:

Newton F. Crenshaw became Vice President - Lilly Oncology Global Business Development and Advocacy for Eli Lilly and Company (Lilly) in July, 2011. He had previously served as Global business-to-payer, bio-medicines & corporate affairs and Crenshaw is a member of the company’s senior management council.

He received a Bachelor of Arts degree with honors in economics from DePauw University in 1985, where he was named a Management Fellow in the university’s honors program in the Center of Management and Entrepreneurship.

Crenshaw joined Lilly in 1985 as a sales representative in Charlottesville, Virginia. In 1988, he became a marketing analyst and served as a government pricing associate in 1989. Later that year, he was named manager of the Nashville district. In 1992, he became manager of marketing research (oral antibiotics and central nervous system). Two years later, he was named regional sales director of the south central area.

Crenshaw served as team leader of business-to-business customer strategy and implementation in 1997, where he built the company’s business-to-business capability in the U.S. market. He was promoted to vice president, U.S. sales and marketing (primary care and neuroscience), in 1999. He was named vice president of e.Lilly, which was formed in July 2000 to accelerate the use of new business models through the use of digital technologies, as well as the initiation of Lilly’s first venture investment fund. In August 2002, he became vice president of communications and public affairs. He served as president and general manager of Lilly Japan from August 2003 to July 2008. In July 2008, he became vice president, global public policy, pricing, reimbursement & access (PRA) and international corporate affairs. Crenshaw serves on several outside boards and chaired PhRMA’s executive committee in Japan.

×

PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Linda House
Executive Vice President of External Affairs, Cancer Support Community

Read biography×

Linda House
Executive Vice President of External Affairs, Cancer Support Community

Follow Linda on:

Linda House joined the Cancer Support Community in February 2012 as Executive Vice President of External Affairs where she oversees the development, communications, and public policy efforts of the national organization.  Linda joined CSC with around 30 years of experience working in the cancer care environment, 17 years being direct patient care in the acute and hospice care setting.

Immediately prior to joining CSC, Linda served as Executive Director of St. Vincent Cancer Care in Indianapolis where she led a team of individuals to provide care across the cancer continuum.  Prior to that, Linda was Senior Director of Advocacy and Professional Relations for Lilly Oncology working with patient and professional organizations on programs and broad issues related to cancer care.

Linda has served in a variety of roles in the national cancer community including Board Chair for Y-ME National Breast Cancer Organization, C-Change Together's Value of Cancer Care and Workforce panels, the National Cancer Institute Director's Consumer Liaison Group, the Education Network to Advance Cancer Clinical Trials Collaborative expert panel, and the patient advisory board for the Patent Resource Cancer Guide to name a few.  Linda is also an active volunteer with a number of organizations in her local community.

×

PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Leonard Lichtenfeld
M.D., MACP, Deputy Chief Medical Officer, American Cancer Society

Read biography×

Leonard Lichtenfeld
M.D., MACP, Deputy Chief Medical Officer, American Cancer Society

Follow Leonard on:

Dr. Lichtenfeld currently serves as Deputy Chief Medical Officer for the American Cancer Society in the Society's Office of the Chief Medical Officer located at the Society's Corporate Center in Atlanta.

Dr. Lichtenfeld joined the Society in 2001 as a medical editor, and in 2002 assumed responsibility for managing the Society's then newly created Cancer Control Science Department which included the prevention and early detection of cancer, emerging cancer science and trends, health equity, quality of life for cancer patients, the science of cancer communications and the role of nutrition and physical activity in cancer prevention and cancer care. 

In 2014, Dr. Lichtenfeld assumed his current role in the Office of the Chief Medical Officer where he provides extensive support to a number of Society colleagues and activities. As a result of his over four decades of experience in cancer care, Dr. Lichtenfeld is frequently quoted in the print and electronic media regarding the Society's positions on a number of important issues related to cancer. He has testified regularly in legislative and regulatory hearings, and participated on numerous panels regarding cancer care, research, advocacy and related topics. He has served on a number of advisory committees and boards for organizations that collaborate with the Society to reduce the burden of cancer nationally and worldwide. He is well known for his blog (www.cancer.org/drlen) which first appeared in 2005 and which continues to address many topics related to cancer research and treatment.

A board certified medical oncologist and internist who was a practicing physician for over 19 years, Dr. Lichtenfeld has long been engaged in health care policy on a local, state, and national level.  He is active in several state and national medical organizations and has a long-standing interest in professional legislative and regulatory issues related to health care including physician payment, medical care delivery systems, and health information technology.

Dr. Lichtenfeld is a graduate of the University of Pennsylvania and Hahnemann Medical College (now Drexel University College of Medicine) in Philadelphia.  His postgraduate training was at Temple University Hospital in Philadelphia, Johns Hopkins University School of Medicine and the National Cancer Institute in Baltimore. He is a member of Alpha Omega Alpha, the national honor medical society.  Dr. Lichtenfeld has received several awards in recognition of his efforts on behalf of his colleagues and his professional activities.  He has been designated a Master of the American College of Physicians in acknowledgement of his contributions to internal medicine. 

Dr. Lichtenfeld is married, and resides in Atlanta and Thomasville, Georgia.

×

PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Stephen Eck
M.D., Ph.D.,Vice President and Global Head of Oncology, Astellas Pharma Global Dev

Read biography×

Stephen Eck
M.D., Ph.D.,Vice President and Global Head of Oncology, Astellas Pharma Global Dev

Follow Stephen on:

Stephen Eck, M.D., Ph.D, is Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development, including both early phase clinical studies and late-stage drug development studies. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. An essential part of this work was conducted in the Diagnostic and Experimental Medicine Group and the Laboratory for Experimental Medicine. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).

Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science. He serves on the Scientific Advisory Board of the ACGT Foundation, which supports academic cancer research, and is a member of the Scientific Advisory Committee of the Fairbanks Institute, an institution dedicated to developing data banks to enable personalized medicine. He also serves on the Advisory Board of the Keck Graduate School (Claremont, CA), and is a Board member of the Personalized Medicine Coalition.

×

PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Roy Herbst
M.D., PhD.; Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology; Associate Director for Translational Research; Clinical Research, Yale Cancer Center

Read biography×

Roy Herbst
M.D., PhD.; Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology; Associate Director for Translational Research; Clinical Research, Yale Cancer Center

Follow Roy on:

Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.

He is a member of the American Association for Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a vice chair of the Southwest Oncology Group’s lung committee, a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

Dr. Herbst received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. He completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.

×

06/05/14: We all want to better prevent, treat and cure the many forms of cancer. How close is the collaborative research ecosystem to achieving these goals, and what do we have to do to get there?

Back to Top

Contributors:

      
Josh Schafer, MSc. MBA, Vice President, Oncology Global Marketing Strategy, Astellas Pharmaceuticals
Rafael Amado, Senior Vice President, Oncology R&D, GlaxoSmithKline
Salvatore Alesci , VP, Scientific & Regulatory Affairs, PhRMA

Join The Conversation

05/23/14: How do we promote patient-centered cancer research and care in an era of increasing pressure to control healthcare costs?

Back to Top

Contributors:

        
Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare
Randy Burkholder, VP, Policy, PhRMA
Margaret Foti, CEO, AACR
Gwen Darien , Executive Vice President, CSC

Join The Conversation

05/08/14: What needs to happen to ensure that ‘treatment’ is front and center in America’s ongoing conversation on mental illness?

Back to Top

Contributors:

            
Dr. Bill Chin, EVP, Scientific & Regulatory Affairs, PhRMA
Christine Moutier , Chief Medical Officer, AFSP
Thomas Insel , Director, NIMH
Torsten Madsen , CMO and VP of US Drug Development, Lundbeck
Charles Ingoglia, Senior Vice President, Public Policy and Practice Improvement, The National Council
Allen Doederlein, President, DBSA

Join The Conversation

Pages